(307 days)
PMA# P890045
No
The summary describes a passive fabric patch and does not mention any computational or analytical capabilities.
Yes
The device is a vascular patch used for grafting and patching, which directly treats or alleviates a medical condition.
No
The device description clearly states it is a fabric for vascular patch grafting and intracardiac patching, which are surgical procedures, not diagnostic activities.
No
The device description clearly describes a physical, implantable fabric product made of polyester, gelatin, and fluoropolymer coating, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for vascular patch grafting and intracardiac patching, which are surgical procedures performed in vivo (within the body). IVDs are used to examine specimens in vitro (outside the body) to provide information about a patient's health.
- Device Description: The device is a fabric patch designed for implantation. This is consistent with a surgical implant, not a diagnostic test.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, reagents, or any other components typically associated with in vitro diagnostics.
- Performance Studies: The performance studies described focus on mechanical properties (burst strength, suture retention, tensile strength, water porosity) and in vivo animal testing, which are relevant to the performance of an implantable device, not an IVD.
Therefore, the Sulzer Vascutek Fluoropassiv™ Fabric is a surgical implant, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Sulzer Vascutek Fluoropassiv™ Fabric is indicated for vascular patch grafting and for intracardiac patching. The Fluoropassiv™ Thin Wall Carotid Patch is, in addition, indicated for patch closure after endarterectomy, particularly of the carotid arteries.
Product codes (comma separated list FDA assigned to the subject device)
74 DXZ
Device Description
The Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric product line consists of a non-crimped Gelseal™ patch, Gelsoft™ patch, and a Thin Wall Carotid patch. Each product line is fluoropolymer coated and gelatinsealed, knitted polyester, with a base fabric porosity of 1433 ml/cm²/min, and 3495 ml/cm²/min, respectively, and are available in various square or rectangular sizes. The polyester fabrics have been impregnated with an absorbable mammalian gelatin which seals the prostheses in the same manner as the fibrin deposited in traditional procedures. The gelatin sealant obviates the need for preclotting prior to implantation. The gelatin is of United States Pharmacopeia (USP) standard and is derived from bovine bone. The result is a family of cardiovascular patches that do not require precloting even when patients have been anticoagulated or when bleeding is a prime concern. The gelatin has been shown to be safe and effective through the approval of the Sulzer Vascular Gelseal™ Vascular Graft, PMA# P890045 on January 11, 1993.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Cardiovascular system (for vascular patch grafting and intracardiac patching), particularly carotid arteries (for patch closure after endarterectomy).
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comprehensive in vitro performance testing has been performed on Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric. In vitro performance testing performed for the Sulzer Vascutek Fluoropassiv™ Fabric and Sulzer Vascutek Cardiovascular Fabric, which included burst strength, suture retention, tensile strength and water porosity, provides evidence that Sulzer Vascutek Fluoropassiv™ Fabric is substantially equivalent to the predicate fabric. In addition, animal testing demonstrates acceptable in vivo performance for the Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
PMA# P890045
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3470 Intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene.
(a)
Identification. An intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene is a fabric device placed in the heart that is used to repair septal defects, for patch grafting, to repair tissue, and to buttress sutures.(b)
Classification. Class II (performance standards).
0
SULZER MEDICA
Sulzer Carbomedics Inc.
1300 East Anderson Lane Austin, Texas 78752-1793
Phone (512) 435-3200 FAX (512) 435-3350 WATS (800) 648-1579 (US and Canada)
510(k) SUMMARY
SULZER VASCUTEK FLUOROPASSIV™ CARDIOVASCULAR FABRIC
The Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric product line consists of a non-crimped Gelseal™ patch, Gelsoft™ patch, and a Thin Wall Carotid patch. Each product line is fluoropolymer coated and gelatinsealed, knitted polyester, with a base fabric porosity of 1433 ml/cm²/min, and 3495 ml/cm²/min, respectively, and are available in various square or rectangular sizes. The polyester fabrics have been impregnated with an absorbable mammalian gelatin which seals the prostheses in the same manner as the fibrin deposited in traditional procedures. The gelatin sealant obviates the need for preclotting prior to implantation. The gelatin is of United States Pharmacopeia (USP) standard and is derived from bovine bone. The result is a family of cardiovascular patches that do not require precloting even when patients have been anticoagulated or when bleeding is a prime concern. The gelatin has been shown to be safe and effective through the approval of the Sulzer Vascular Gelseal™ Vascular Graft, PMA# P890045 on January 11, 1993.
Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric is indicated for vascular patch grafting and for intracardiac The Fluoropassiv™ Thin Wall Carotid Patch is, in addition, indicated for patch closure after patching. endarterectorny, particularly of the carotid arteries. Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric is manufactured from materials that have an extensive history of use in cardiovascular and other medical This polyester material, fluoropolymer, and gelatin sealant have been thoroughly tested and applications. characterized with regard to biocompatibility and suitability for their intended use. Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric is supplied sterilization used is Ethylene Oxide. A shelf-life of 4 years has been established.
Comprehensive in vitro performance testing has been performed on Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric. In vitro performance testing performed for the Sulzer Vascutek Fluoropassiv™ Fabric and Sulzer Vascutek Cardiovascular Fabric, which included burst strength, suture retention, tensile strength and water porosity, provides evidence that Sulzer Vascutek Fluoropassiv™ Fabric is substantially equivalent to the predicate fabric. In addition, animal testing demonstrates acceptable in vivo performance for the Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric.
Sulzer Carbomedics considers Vascutek Fluoropassiv™ Cardiovascular Fabric safe, effective and substantially equivalent in intended use and function to the Sulzer Vascutek Cardiovascular Fabric which received marketing clearance on November 21, 1996, under 510(k) K963611.
| Common name of the Device: | Cardiovascular Patch |
|---|---|
| Trade name of Proprietary Name: | Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric: |
| Sulzer Vascutek Fluoropassiv™ Gelseal™ Patch | |
| Sulzer Vascutek Fluoropassiv™ Gelsoft™ Patch | |
| Sulzer Vascutek Fluoropassiv™ Thin Wall Carotid Patch | |
| Submitter and Contact Person: | Edward E. Newton, Sr. Regulatory Affairs Specialist |
| 1300 E. Anderson Lane, Austin, TX 78752 | |
| Phone: (512) 435-3407 Fax: (512) 435-3350 | |
| Submission Submitted on: | June 10, 1997 |
7
1
Image /page/1/Picture/2 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name encircling a stylized caduceus symbol. The caduceus is a symbol of medicine and health, and it is depicted with a staff entwined by two snakes and topped with wings.
APR 1 4 1998
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Edward E. Newton Sr. Regulatory Affairs Specialist Sulzer Carbomedics, Inc. 1300 East Anderson Lane Austin, TX 78752-1793
K972201 Re: Sulzer Vascutek Fluoropassiv™ Cardovascular Fabric Regulatory Class: II (Two) Product Code: 74 DXZ Dated: April 1, 1998 Received: April 2, 1998
Dear Mr. Newton:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is . . substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval); it may be-subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2 - Mr. Edward E. Newton
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html."
Sincerely yours,
Thomas J. Callahan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if known): K972201
Device Name:_ Sulzer Vascutek Fluoropassiv™ Cardiovascular Fabric
Indications For Use: Sulzer Vascutek Fluoropassiv™ Fabric is indicated for vascular patch grafting and for intracardiac patching. The Fluoropassiv™ Thin Wall Carotid Patch is, in addition, indicated for patch closure after endarterectomy, particularly of the carotid arteries.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
tere R. Linyera
(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number_________________________________________________________________________________________________________________________________________________________________
Prescription Use X (Per 21 CFR 801.109)
. OR
Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)